Based on immunoreactivity, Akimoto et al. [108] indicated that F11R/JAM-A or claudin-1 could be used as biomarkers for distinguishing cervical adenocarcinoma from non-neoplastic glands with high sensitivity (F11R/JAM-A with a higher rate) and specificity (both at the same rate) [108]. The gene discussed is F11R; the disease is cervical adenocarcinoma.